Oxford Halts Vaccine Trial; ‘On Hold’ after Participant Experiences Adverse Reaction! - Report

The Oxford vaccine, which was being developed with AstraZeneca has been undergoing the final stage of clinical trials in several countries. However, the process was put on hold after it triggered a serious and adverse reaction in one of the study participant.

The Stat News reported on Tuesday, that this highly anticipated COVID-19 vaccine candidate has now not stood up to its safety expectations. In a statement, AstraZeneca said, “standard review process triggered a pause to vaccination to allow review of safety data.” The adverse event was reported in three sites according to a report published by The Hindu. The three sites include, India, the United States and the United Kingdom.

The exact nature of the safety issue has not been made public yet. However, Stat News’ report claims that the participant is expected to recover soon. Several companies which are developing vaccines including AstaZeneca had issued a historic pledge earlier. The pledge was taken to ensure that the safety standards are met.

The companies said that they would, “uphold the integrity of scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.”